Global investment firm All Blue Capital has offered to buy Zymeworks, a public biotech company based in Vancouver, B.C., with operations in Seattle. All Blue delivered a letter to the… Read More
Zymeworks is looking to raise $100 million in a public offering, barely a week since new CEO Kenneth Galbraith took the reins of the biotech company, which has operations in… Read More
Kenneth Galbraith is shaking up Zymeworks within a week of becoming CEO of the Seattle and Vancouver, B.C.-based biotech company. He announced major leadership changes in a statement Wednesday, and… Read More
— Chad Cohen will step down as CFO of Adaptive Biotechnologies on Feb. 15. Prior to joining Adaptive in 2015, Cohen was CFO of Zillow Group. Principal accounting officer Kyle… Read More